Manufacturing & Packaging

Expansion expected to double batch capacity

Includes a 36,000-square-foot addition to Charlottetown location

Includes 100,000 square feet of controlled ambient storage

Campus will feature a CDMO, over 1,000,000 square feet of floor space

Company strives to provide essential medicines that are in low supply

CDMO will invest up to $160 million toward manufacturing of therapies and vaccines, including mRNA

Features growth of cold storage, visual inspections capacity

Collective project expected to enhance the manufacturing supply chain for ATMPs within the UK

Will have capability of producing 300 million COVID-19 vaccines for Africa annually

How CDMOs will lead the way toward true cloud lab enablement

Site construction is part of a 10-year agreement with the Australian government

It has become critical to provide real-time accurate labeling information to labeling teams and healthcare providers as soon as a product change is approved by regulators. IQVIA‘s Cham Williams discusses the technology needed to support this shift and how these new solutions will minimize risks associated with regulatory compliance and increase patient safety.

Accreditation further extends CDMO's viral vector manufacturing capacity

Acquisition expected to be finalized in April

Survey conducted by HDA reveals thought process of manufacturers, distributors, and 3PLs

Moderna, Pfizer, and BioNTech seeking FDA approval for fourth dose of their respective shots

New center comes in response to increasing demand for firm’s medicines

CDMO’s Chenôve facility receives investment from French government

Deal expected to help expand its API production services

Agreement establishes company’s first mRNA manufacturing facility in Africa

The deal features a long-term supply and production agreement between the parties

Expansion features 11 new cGMP labs at Durham, NC location

A chat with Cardinal Health’s Joel Wayment, who dives into what can be done to help ensure that patients receive their necessary medications, no matter the conditions

The parties are partnering up to leverage dedicated commercial fill-finish manufacturing capacity in the US for mRNA vaccines and therapies

Turnkey centers will promote scalable vaccine production for an end-to-end manufacturing network for mRNA-based vaccines in Africa

CDMO obtains both Vibalogics and Arranta Bio to increase presence in the sector

Will establish presence in Belgium, Denmark, Norway, the Netherlands, Poland and Sweden

Plans are underway to build Scottish fill-finish center, renovate API facility in England

The solution is a combination of cold chain logistics, serialization compliance and distribution

With the deal, the China-based CDMO grows its US presence